



2024

# Taipei International Breast Cancer Symposium

台北國際乳癌研討會

## Speech Abstract

Topic:

**Current Status and Future Prospects of Immunotherapy in Breast Cancer Treatment: Past, Present, and Future**

Abstract

Immunotherapy has emerged as a promising approach for breast cancer treatment, leveraging the body's immune system to target cancer cells more effectively. Today's talk will enclose the historical context of immunotherapy in breast cancer, highlighting the early attempts and subsequent advancements that have paved the way for its current utilization.

Recent update of clinical trials and outcomes shed light on the efficacy and safety profiles of immunotherapy as a single agent or in combination with other treatment modalities. KEYNOTE-355 already demonstrated the value of pembrolizumab in advanced TNBC(triple negative breast cancer). KEYNOTE-522 showed an OS benefit of perioperative pembrolizumab plus in resectable TNBC. And now, KEYNOTE-756 and CHECKMATE-7FL showed increased pathologic complete response rate in patients with hormone receptor positive and Her2 negative resectable breast cancers.

Furthermore, ongoing research efforts and future prospects aim to enhance the efficacy of immunotherapy in breast cancer. These prospects include the immunotherapeutic approaches tailored to different breast cancer subtypes.